Malcontenti-Wilson C - Search Results

1

Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases.

Fifis T, Lam I, Lin D, Malcontenti-Wilson C, Christophi C, Loveland B. Fifis T, et al. Vaccine. 2008 Jan 10;26(2):241-9. doi: 10.1016/j.vaccine.2007.10.068. Epub 2007 Nov 21. Vaccine. 2008. PMID: 18069095

2

Lymphatic patterns of colorectal liver metastases.

Hadj AK, Malcontenti-Wilson C, Nikfarjam M, Christophi C. Hadj AK, et al. J Surg Res. 2012 Apr;173(2):292-8. doi: 10.1016/j.jss.2010.09.012. Epub 2010 Oct 8. J Surg Res. 2012. PMID: 21035136

3

Interstitial laser hyperthermia and the biological characteristics of tumor: study in a murine model of colorectal liver metastases.

Muralidharan V, Nikfarjam M, Malcontenti-Wilson C, Christophi C. Muralidharan V, et al. J Clin Laser Med Surg. 2003 Apr;21(2):75-83. doi: 10.1089/104454703765035493. J Clin Laser Med Surg. 2003. PMID: 12737647

4

Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis.

Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C. Chan LS, et al. Anticancer Res. 2007 Jul-Aug;27(4B):2317-23. Anticancer Res. 2007. PMID: 17695520 Free article.

5

Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases.

Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Neo JH, et al. J Gastroenterol Hepatol. 2007 Apr;22(4):577-84. doi: 10.1111/j.1440-1746.2006.04797.x. J Gastroenterol Hepatol. 2007. PMID: 17376054

6

Alterations in vascular architecture and permeability following OXi4503 treatment.

Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C. Chan LS, et al. Anticancer Drugs. 2008 Jan;19(1):17-22. doi: 10.1097/CAD.0b013e3282f077a1. Anticancer Drugs. 2008. PMID: 18043126

7

P-21 activated kinase 1 knockdown inhibits β-catenin signalling and blocks colorectal cancer growth.

He H, Huynh N, Liu KH, Malcontenti-Wilson C, Zhu J, Christophi C, Shulkes A, Baldwin GS. He H, et al. Among authors: malcontenti wilson c. Cancer Lett. 2012 Apr 1;317(1):65-71. doi: 10.1016/j.canlet.2011.11.014. Epub 2011 Nov 15. Cancer Lett. 2012. PMID: 22100495

8

Physiological characterization of a mouse model of cachexia in colorectal liver metastases.

Murphy KT, Struk A, Malcontenti-Wilson C, Christophi C, Lynch GS. Murphy KT, et al. Among authors: malcontenti wilson c. Am J Physiol Regul Integr Comp Physiol. 2013 May 15;304(10):R854-64. doi: 10.1152/ajpregu.00057.2013. Epub 2013 Mar 13. Am J Physiol Regul Integr Comp Physiol. 2013. PMID: 23485871 Free article.

9

Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor.

Fifis T, Nguyen L, Malcontenti-Wilson C, Chan LS, Nunes Costa PL, Daruwalla J, Nikfarjam M, Muralidharan V, Waltham M, Thompson EW, Christophi C. Fifis T, et al. Among authors: malcontenti wilson c. Cancer Med. 2013 Oct;2(5):595-610. doi: 10.1002/cam4.109. Epub 2013 Aug 18. Cancer Med. 2013. PMID: 24403226 Free PMC article.

10

Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.

Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE. Malcontenti-Wilson C, et al. Clin Cancer Res. 2001 Apr;7(4):1052-60. Clin Cancer Res. 2001. PMID: 11309357

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page